title: Survival outcome and neurotoxicity in patients of high-grade gliomas treated with conformal radiation and temozolamide.
abstract: BACKGROUND
  To study the survival outcome and neurotoxicity grades in patients of high-grade glioma (HGG) treated with conformal radiation and temozolamide.
  
  
  METHODS
  Forty-six patients of HGG received conformal post operative radiation and temozolamide in the period 2003 to 2007. Twenty seven patients had near total resection, 17 had subtotal resection and 2 had biopsy only. 33 patients (71.7%) were treated with IMRT and 13 (28.3%) received 3DCRT (conformal radiation). Median dose delivered to PTV2 was 61.58 Gy and PTV1 was 54.3 Gy. Neurotoxicity was assessed with sequential MRI and cognitive disturbance was evaluated and grading was done according to CTCAE version 2.0 and 3.0 respectively.
  
  
  RESULTS
  At a median follow-up of 12 months, median progression free and overall survival was 9 months and 15 months respectively. At 6 months, MRI neurotoxicity of grade 1, 2, and 3 was seen in 34.3, 11.4 and 2.9% patients. At 24 months, 35.3 and 29.4% patients had grade 1 and 2 neurotoxicity respectively. Cognitive disturbance was grade 0, 1, 2 and 3 in 55, 34.4, 6.8 and 3.4% patients at 6 months and grade 0 and grade 1 in 51.1 and 42.8% patients respectively at 24 months.
  
  
  CONCLUSIONS
  Conformal Radiation yields low grades of MRI assessed neurotoxicity and cognitive disturbance in patients of HGG with no adverse impact on local control and survival.
authors.affiliation: Department of Radiation Oncology, Ganga Ram Hospital, Delhi, India. akanand@maxhealthcare.com
authors.forename: Anil Kumar
authors.initials: AK
authors.lastname: Anand
authors.forename: Amal Roy
authors.initials: AR
authors.lastname: Chaudhory
authors.forename: Har Narain
authors.initials: HN
authors.lastname: Aggarwal
authors.forename: Pushpender Kumar
authors.initials: PK
authors.lastname: Sachdeva
authors.forename: Pritam Singh
authors.initials: PS
authors.lastname: Negi
authors.forename: Sujit Nath
authors.initials: SN
authors.lastname: Sinha
authors.forename: Ananda Giri
authors.initials: AG
authors.lastname: Babu
authors.forename: Amarnath
authors.initials: A
authors.lastname: Jena
authors.forename: Avinash
authors.initials: A
authors.lastname: Rao
authors.forename: Partha S
authors.initials: PS
authors.lastname: Chaudhury
mesh_terms: D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy*; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005910:Glioma / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D011879:Radiotherapy Dosage; D020266:Radiotherapy, Conformal / Q000009:adverse effects; D016019:Survival Analysis; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide